Johnson & Johnson Innovation Names Awardees of the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity


Johnson & Johnson Innovation in collaboration with the Office of the Chief Medical Officer of The Johnson & Johnson Family of Companies (OCMO) Health of Women team, together with The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that Acclinate and NX Prenatal Inc. have been selected as the awardees in the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity.

The challenge invited innovators to submit data-driven research methodologies, tools, or technologies that aim to better understand the manifestation of immune-mediated diseases of pregnancy impacting historically marginalized communities.

Acclinate is a trusted digital health company that leverages its NOWINCLUDED and e-DICT platforms with the aim to help research sponsors engage, and educate communities of color to make clinical research more inclusive.

NX Prenatal Inc. is a molecular diagnostics company recognized for its innovative work in utilizing a novel exosome-based liquid biopsy platform to develop enabling, early warning systems for pregnancies that may result in adverse outcomes.

Acclinate and NX Prenatal Inc. will receive grant funding from a total pool of $500,000, access to the global Johnson & Johnson Innovation – JLABS network, and mentorship from experts across the Johnson & Johnson Family of Companies (Johnson & Johnson).

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s great healthcare challenges.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation, LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation—JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit:

Last modified: December 3, 2023